aTyr Pharma Inc

Financials

Activos totales 38.73 M115.54 M95.79 M120.65 M96.83 M93 M Total de pasivos 7.24 M6.41 M24.5 M30.18 M27 M25.71 M Capital total 31.48 M109.13 M71.28 M90.47 M69.83 M67.29 M Total de pasivos y patrimonio neto 38.73 M115.54 M95.79 M120.65 M96.83 M93 M Deuda total —————— Deuda neta ——————

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.